View Document Preview and Link Document Date: 2011-04-13 14:33:29 Open Document File Size: 1,00 MB Share Result on Facebook
City Cancer Inst. / / Company Medulloblastoma / PD2 NB-EBc1 Neuroblastoma / Neuroblastoma / Ependymoma / Osteosarcoma / / Country United States / Australia / / Facility Hospital of Philadelphia / Jude Children’s Research Hospital / Stable Disease / duPont Hospital / Hospital ABSTRACT Background / / MedicalCondition tumor / NB-SD Neuroblastoma / tumors / D645 D456 Glioblastoma Glioblastoma Glioblastoma Glioblastoma / Ependymoma / PD2 NB-EBc1 Neuroblastoma / solid tumor / progressive disease / Osteosarcoma / neuroblastoma / acute lymphoblastic leukemia / ALV RMS Medulloblastoma / sarcoma / Medulloblastoma / Stable Disease / perpendicular tumor / MGMTnegative tumors / childhood solid tumors / MGMT-negative tumors / astrocytoma / SC tumors / rhabdomyosarcoma / / OperatingSystem OS-2 / OS-9 / / Organization Peter J. Houghton9 1Duke University / Jude Children’s Research Hospital / duPont Hospital / 4Children's Hospital / 7Children’s Hospital of Philadelphia / FDA / 6Texas Tech University Health Science Center / / Person Jude Children / / Product dacarbazine / sterile water / / SportsEvent NHL / / Technology genotype / / URL http / SocialTag 
PEDIATRIC PRECLINICAL TESTING PROGRAM (PPTP) EVALUATION OF THE DNA METHYLATING AGENT TEMOZOLOMIDE #5356 Stephen T. Keir1, Christopher Morton2, E. Anders Kolb3, Richard Gorlick4, Hernan Carol5, Richard B. Lock5, Min Kang6